Citation

  • Authors: Bery, N., Keller, L., Soulié, M., Iscache, A. L., Gence, R., Cherier, J., Cabantous, S., Sordet, O., Lajoie-Mazenc, I., Pedelacq, J. D., Favre, G., Olichon, A.
  • Year: 2018
  • Journal: Cell Reports
  • Applications: in vitro / DNA, siRNA / jetPRIME
  • Cell types:
    1. Name: HEK-293
      Description: Human embryonic kidney Fibroblast
      Known as: HEK293, 293
    2. Name: HeLa S3
      Description: Human cervix epitheloid carcinoma cells
    3. Name: NCI-H2882
      Description: Human squamous cell lung carcinoma
      Known as: H2882 ; H-2882 ; NCIH2882
    4. Name: PC-9
      Description: Formely known as PC-14, derived from human lung adenocarcinoma

Method

PC-9: 0,75 μg DNA + 1,5 μL jetPRIME in 96-well plate Lentivirus production

Abstract

The selective down-regulation of activated intracellular proteins is a key challenge in cell biology. RHO small GTPases switch between a GDPbound and a GTP-bound state that drives downstream signaling. To date, no tool is available to study endogenous RHO induced conformational changes in live cells. Here, we set up an original cell-based screen to selectively degrade the RHOB-GTP fraction using nanobodies functionalized with a F-box domain. We identified one selective intrabody that shows selective targeting of endogenous RHOB-GTP mediated by interactions between the intrabody CDR3 loop and the GTP-binding pocket of RHOB. Our results indicate that, while RHOB expression is highly regulated, only the minor GTP-bound fraction but not its global expression mediates RHOB functions in genomic instability and in cell invasion. The F-box/intrabody-mediated protein degradation represents a unique approach to selectively target the active form of small GTPases or other proteins with multiple cellular activities.